#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

Episode Summary

Executive Summary: Peter Attia interviews cardiologist-lipidologist Michael Davidson about lifelong LDL exposure, why prevention should start early, and how obicetrapib may become a powerful new add-on to statins. They review the CETP-inhibitor history, why earlier drugs failed, the emerging evidence for obicetrapib on LDL, ApoB, Lp(a), diabetes risk, and possible Alzheimer’s prevention via HDL and APOE4 biology.

Main Topics: Early prevention and lifelong LDL exposure (Priority: 5/5): Davidson argues ASCVD prevention should begin well before symptoms or events, because cumulative LDL burden drives plaque formation over decades. He frames LDL like smoking or blood pressure: treat the causal factor early, not just short-term risk. CETP inhibitor history and why earlier drugs failed (Priority: 5/5): The conversation reviews torcetrapib, dalcetrapib, and evacetrapib. Torcetrapib failed due to off-target aldosterone/blood-pressure effects; dalcetrapib was safe but ineffective on outcomes; evacetrapib likely stopped too early. Merck’s anacetrapib later validated CETP inhibition through LDL lowering. Obicetrapib’s clinical profile and cardiovascular potential (Priority: 5/5): Obicetrapib is presented as a more potent CETP inhibitor with strong LDL lowering at low dose, meaningful HDL increases, and favorable signals in phase 2/3 trials. The hosts discuss its likely place as a companion to statins and possibly ezetimibe. Biomarkers: ApoB, LDL-P, non-HDL, and Lp(a) (Priority: 4/5): They debate discordance among ApoB, LDL particle number, and LDL-C, and how CETP inhibition appears to lower small LDL particles strongly while affecting ApoB less dramatically. Obicetrapib also lowers Lp(a) by about 50%, making it relevant to residual risk management. Alzheimer’s disease, APOE4, and HDL biology (Priority: 5/5): Davidson explains why HDL and CETP may matter in neurodegeneration: APOE4 impairs brain lipid handling, HDL interfaces with the brain, and CETP inhibition may improve cholesterol transport, sterol clearance, and cognitive biomarkers. The hosts discuss PTau 217 and other markers as potential surrogate endpoints. Omega-3s, DHA delivery, and AI in drug development (Priority: 3/5): The episode closes with a discussion of EPA vs DHA, the limits of prior omega-3 trials, a new DHA transport mechanism (Mfsd2a and lyso-PC DHA), and how AI could streamline clinical trials and improve efficiency in drug development.

Key Arguments: LDL is a causal driver of ASCVD, so it should be treated early in life, not only when short-term risk becomes high. The 'eight-gram rule' suggests cumulative lifetime LDL exposure is what matters most for plaque formation. Earlier CETP inhibitors failed largely because of off-target toxicity or inadequate trial design, not because CETP was an invalid target. Anacetrapib provided proof of concept that CETP inhibition can reduce cardiovascular events when LDL is lowered. Obicetrapib appears more potent and better tolerated than prior CETP inhibitors, with substantial LDL lowering at very low doses. Obicetrapib may fit best as an add-on to statins, helping lower LDL, ApoB-related risk, small LDL particles, diabetes risk, and Lp(a). HDL is biologically complex; high HDL alone is not necessarily protective, and genetics can produce high HDL with increased risk. The APOE4-Alzheimer’s hypothesis is plausible because brain lipid metabolism is tightly linked to HDL/ApoE biology, and CETP inhibition may influence relevant biomarkers. PTau 217 and related biomarkers may become useful for earlier Alzheimer’s risk detection and possibly future regulatory endpoints. AI could meaningfully accelerate clinical trials if it helps model actual drug-taking behavior and reduces dilution from nonadherence.

Data Points: Michael Davidson's publication record: 350+ peer-reviewed papers - Introduced as part of his lipidology and prevention background Clinical trials coordinated: 1,000+ trials - Used to establish Davidson’s experience in drug development Books authored: 3 books - On lipid disorders and cardiovascular prevention Father’s age at death: 47 - Family history that shaped Davidson’s focus on prevention Age Davidson was when his father died: 16 - Personal motivation for early lipid treatment Lifetime LDL exposure example: 8 grams - The 'eight-gram rule' used to illustrate cumulative cholesterol burden LDL examples for 8 grams: 200 mg/dL for 40 years; 100 mg/dL for 80 years; 80 mg/dL for 100 years - Illustration of lifetime cholesterol exposure Torcetrapib HDL increase: ~75% - Large HDL rise that initially made CETP inhibition seem promising Torcetrapib LDL effect: ~10–15% - Relatively modest LDL lowering in that program Torcetrapib blood pressure increase: ~3–5 points - Early off-target signal before the outcome trial failure Dalcetrapib HDL increase: ~30–40% - Weak CETP inhibitor with safety but no MACE benefit Evacetrapib LDL lowering: ~15–20% - Outcome trial did not show MACE benefit, likely due to short duration and early stop Evacetrapib HDL increase: ~75% - Strong HDL effect similar to earlier CETP inhibitors Anacetrapib LDL lowering: 17% - Merck outcome study showing proof that CETP inhibition can reduce events Anacetrapib absolute LDL reduction: 11 mg/dL - In a study with baseline LDL around 60 mg/dL Anacetrapib relative risk reduction: 9% - Cardiovascular outcome benefit in a large trial Anacetrapib study size: 30,000 patients - Described as a very large outcome trial Obicetrapib phase 2 LDL lowering: ~45% - Tulip study and early data Obicetrapib HDL increase: ~150% - Described as a strong HDL-raising effect Rose II LDL lowering: 45–50% - Phase 3 monotherapy signal Broadway LDL lowering: ~35% - ASCVD phase 3 trial on top of maximal statins Broadway MACE reduction signal: 21% - One-year signal, not yet statistically significant due to sample size Tandem LDL lowering: ~50% - Obicetrapib plus ezetimibe combination trial Brooklyn LDL lowering: ~40% - Familial hypercholesterolemia trial over 1 year Brooklyn baseline LDL: ~100 mg/dL - Despite maximal background therapy, including statins and often ezetimibe/PCSK9 inhibitors Lp(a) lowering with obicetrapib: ~50% - Range described as 50–150 mg/dL baseline-dependent reduction Statin diabetes signal: Small but real increase - Raised as a class effect and a counseling issue PTau 217 reduction in older/APOE4 subgroup: >20% difference vs placebo - Broadway biomarker analysis in higher-risk subgroups Cognitive biomarker study sample: ~13 APOE4 patients - Small Amsterdam pilot in mild cognitive impairment Broadway biomarker sample: 2,500 patients - Pre-specified biomarker analyses in a phase 3 ASCVD study PREVAIL trial size: 9,500 patients - Global secondary-prevention outcome trial for obicetrapib PREVAIL geography: 400+ sites worldwide - Global cardiovascular outcomes study Minimum follow-up for PREVAIL: 2.5 years - Designed to account for delayed event separation Omega-3 trial dose: 4 grams - Strength trial dose mentioned in relation to EPA/DHA APOE4 prevalence: ~25% of the population - Used to highlight the potential market and clinical importance for Alzheimer’s prevention APOE4 homozygote Alzheimer’s risk: ~10x - As described in the discussion of genetic risk APOE3/4 Alzheimer’s risk: ~3x - Intermediate risk compared with APOE3/3 ApoE2 effect: Lower risk / longevity-associated - Described as a favorable longevity genotype

Pivotal Quotes: "LDL is causal and we know that. So, why not treat it early as you can in life?" — Michael Davidson: Arguing for primordial prevention and early lipid lowering "What we had was a genomic validation that if you have the clotho gene, you're protected against Alzheimer's." — Michael Davidson: Explaining why he believes CETP/HDL biology could matter in neurodegeneration "We can now get lyso-PC DHA... It’s on the horizon." — Michael Davidson: Discussing a potential next-generation DHA strategy for brain delivery

Implications: If PREVAIL is positive, obicetrapib could become a major oral add-on for residual LDL/Lp(a)/diabetes risk and may open a prevention pathway for Alzheimer’s, especially in APOE4 carriers. The episode also argues for earlier, more aggressive, biomarker-informed prevention across cardiometabolic disease.